Haematologica (Aug 2018)
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
- Guillaume Cartron,
- Rémi Letestu,
- Caroline Dartigeas,
- Mira Tout,
- Béatrice Mahé,
- Anne-Laure Gagez,
- Emmanuelle Ferrant,
- Boris Guiu,
- Bruno Villemagne,
- Phan Letuan,
- Thérèse Aurran,
- Frédérique Orsini-Piocelle,
- Anne Banos,
- Pierre Feugier,
- Véronique Leblond,
- Sophie de Guibert,
- Olivier Tournilhac,
- Jehan Dupuis,
- Alain Delmer,
- Valérie Rouillé,
- David Ternant,
- Stéphane Leprêtre
Affiliations
- Guillaume Cartron
- Department of clinical hematology, University hospital of Montpellier, France;CNRS UMR 5235, University of Montpellier, France
- Rémi Letestu
- APHP, HUPSSD, Hospital Avicenne, Department of biological hematology, Bobigny, France
- Caroline Dartigeas
- Department of clinical hematology, University hospital of Tours, France
- Mira Tout
- CNRS UMR 7292, François Rabelais University, University hospital of Tours, France
- Béatrice Mahé
- Department of clinical hematology, University hospital of Nantes, France
- Anne-Laure Gagez
- Department of clinical hematology, University hospital of Montpellier, France
- Emmanuelle Ferrant
- Department of clinical hematology, University hospital of Dijon, France
- Boris Guiu
- Department of Radiology, University hospital of Montpellier, France
- Bruno Villemagne
- Department of hematology-oncology, Departmental Hospital La Roche-sur-Yon, France
- Phan Letuan
- Laboratory of Biostatistics, University institute of Clinical Research, Montpellier, France
- Thérèse Aurran
- Paoli Calmette Center, Marseille, France
- Frédérique Orsini-Piocelle
- Department of clinical hematology, Hospital of Annecy, France
- Anne Banos
- Department of clinical hematology, Hospital Côte Basque, Bayonne, France
- Pierre Feugier
- Department of clinical hematology, University hospital of Nancy, France
- Véronique Leblond
- Department of clinical hematology, UPMC University of Paris 6, GRC11, Hospital La Pitié Salpêtrière, France
- Sophie de Guibert
- Department of clinical hematology, University hospital of Rennes, France
- Olivier Tournilhac
- Department of clinical hematology, University hospital of Clermont-Ferrand, France
- Jehan Dupuis
- Fonctional unit Lymphoid malignancies, University hospital Henri Mondor, Créteil, France
- Alain Delmer
- Department of clinical hematology, University hospital of Reims, Rouen, France
- Valérie Rouillé
- Department of clinical hematology, University hospital of Montpellier, France
- David Ternant
- CNRS UMR 7292, François Rabelais University, University hospital of Tours, France;Laboratory of Pharmacology-Toxicology, CNRS, UMR7292, University hospital of Tours, Rouen, France
- Stéphane Leprêtre
- Inserm U1245 and department of hematology, Henri Becquerel Center and university of Normandy UNIROUEN, Rouen, France
- DOI
- https://doi.org/10.3324/haematol.2017.182352
- Journal volume & issue
-
Vol. 103,
no. 8
Abstract
No abstracts available.